Health Care Reform and Possible Effects on Innovative Therapies: Cancer as a Case Study : Hearing Before the Subcommittee on Technology, Environment, and Aviation of the Committee on Science, Space, and Technology, U.S. House of Representatives, One Hundred Third Congress, Second Session, February 2, 1994, Volume 4U.S. Government Printing Office, 1994 - 198 pages |
From inside the book
Results 1-5 of 44
Page 2
... treated at Duke Medical Center and is a constituent of our colleague , Paul McHale . The final witness is Dr. John Curd , who is clinical director of Genentech . We look forward to their tes- timony . And this is the place where I would ...
... treated at Duke Medical Center and is a constituent of our colleague , Paul McHale . The final witness is Dr. John Curd , who is clinical director of Genentech . We look forward to their tes- timony . And this is the place where I would ...
Page 3
... treat it more effectively but enabled the medical people in many cases to avoid intrusive surgical , medical care ... treating cancer of any form in human beings . I think it is a very important issue that we need to explore , so I am ...
... treat it more effectively but enabled the medical people in many cases to avoid intrusive surgical , medical care ... treating cancer of any form in human beings . I think it is a very important issue that we need to explore , so I am ...
Page 13
... treat a broad range of human diseases with gene therapy . According to the article , " chemotherapy for cancer may someday be a matter of taking a pill to switch on poisonmaking genes in cells that have been designed to home in on a ...
... treat a broad range of human diseases with gene therapy . According to the article , " chemotherapy for cancer may someday be a matter of taking a pill to switch on poisonmaking genes in cells that have been designed to home in on a ...
Page 31
... by approximately 50 percent compared with patients who were not treated with G - CSF . The drug costs about $ 1,000 per course of treatment , but by preventing infections it can save roughly $ 7,000 in hospital costs11 222 31.
... by approximately 50 percent compared with patients who were not treated with G - CSF . The drug costs about $ 1,000 per course of treatment , but by preventing infections it can save roughly $ 7,000 in hospital costs11 222 31.
Page 32
... treat diseases and conditions that were previously considered untreatable , for which no effective therapies existed . Alfa - interferon , the hairy cell leukemia example , actually saves the lives of cancer patients . Ceredase , used ...
... treat diseases and conditions that were previously considered untreatable , for which no effective therapies existed . Alfa - interferon , the hairy cell leukemia example , actually saves the lives of cancer patients . Ceredase , used ...
Other editions - View all
Common terms and phrases
administration Administration's antibody areas biotech biotech companies biotech firms biotechnology companies biotechnology industry Biotechnology Industry Organization bone marrow transplant breakthrough drugs breast cancer CANCE cancer cells cancer patients capital Chairman chemotherapy clinical trials Clinton colon cancer colorectal cancer committee competition Congress Curd cures disease doctors drug companies drug costs drug prices effective Federal FELDBAUM funding gene therapy Genentech Genzyme global going health care costs health care reform health care system HOKE hospital human impact increased innovation investment investors issue Japan Johnson KLEIN manufacturing medical device medical device industry medicine million National Cancer Institute overutilization percent pharmaceutical industry prescription President price controls Price Regulation profits proposed protein receptor regulatory research and development result risk spending subcommittee surgery Thank therapeutic Tim Valentine treat TREATMENT OF COLORECTAL tumor United VALENTINE WAGNER-JOHNSON women